Wednesday, July 8, 2026

pharma · Uveal Melanoma · HLA-A2 negative metastatic uveal melanoma · IDYA

IDEAYA Biosciences

IDEAYA Biosciences is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker IDYA. Primary therapeutic focus areas include Uveal Melanoma, HLA-A2 negative metastatic uveal melanom

5000 Shoreline Ct, Suite 300, South San Francisco, California 94080, US HQ
2015 Founded
248 Employees
Public company Type
IDYA · NYSE Ticker
Company details
Status
Public
HQ
5000 Shoreline Ct, Suite 300, South San Francisco, California 94080, US
Founded
2015
Employees
248
Programs
14
Drugs
12
Patents
12
Clinical program

GSK4418959

Phase 2 · small molecule · Neoplasms, Colorectal

GSK4418959 for Neoplasms, Colorectal is a Phase 2 program (small_molecule) at IDEAYA Biosciences with 1 ClinicalTrials.gov record(s).

← All IDEAYA Biosciences projects Phase 2 small molecule active

Internal code 221971

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
IDEAYA Biosciences
Phase
Phase 2
Modality
small_molecule
Indication
Neoplasms, Colorectal
Status
active
Trials
1

Clinical trials